Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.61 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | USP8 | P40818 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1877319 | 0.84 | GRIA1 (0.73) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL1877800 | 0.84 | GRIA1 (0.66) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL1885129 | 0.83 | GRIA1 (0.72) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL17856786 | 0.83 | GRIA1 (0.61) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL13376037 | 0.83 | GRIA1 (0.61) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL1884596 | 0.83 | GRIA1 (0.61) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL1882327 | 0.80 | GRIA1 (0.73) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL13964267 | 0.80 | GRIA1 (0.58) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL28423631 | 0.79 | GRIA1 (0.57) | GRIA1GRIA3PDE4DMEN1KMT2A | |
| SCHEMBL1883680 | 0.79 | GRIA1 (0.57) | GRIA1GRIA3PDE4DMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370555-A1 | METHODS OF PREVENTING PROTEIN AGGREGATION | TrueBinding, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4352105-A2 | ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE | TrueBinding, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4329804-A1 | ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4314298-A1 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATE AND ANTIBODY-PEPTIDE-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Avidity Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4308691-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | Iovance Biotherapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4301138-A2 | TUMOR STORAGE AND CELL CULTURE COMPOSITIONS | Iovance Biotherapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4288140-A1 | ADJUVANT THERAPY FOR CANCER | Iovance Biotherapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023086803-A1 | METHODS OF EXPANSION TREATMENT UTILIZING CD8 TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4139440-A1 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | Iovance Biotherapeutics, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4126066-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1465626-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | Eisai Co., Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1416789-A1 | PROPAGATION OF HUMAN HEPATOBLASTOMA CELL IN NON-HUMAN ANIMALS | The University of Connecticut (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003015506-A1 | PROPAGATION OF HUMAN HEPATOBLASTOMA CELL IN NON-HUMAN ANIMALS | UNIVERSITY OF CONNECTICUT (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.